How Do Mergers and Acquisitions Near Me Work for My Corporation?

M&A transactions take two primary forms: asset purchases (where the buyer acquires specific company assets and liabilities separately), and stock purchases (where the buyer acquires ownership of the entire company). Asset deals shift liability risk to the seller; stock deals typically transfer all liabilities to the buyer unless the purchase agreement specifies otherwise. Structuring the transaction affects tax consequences, successor liability exposure, and post-closing disputes over who bears responsibility for undisclosed problems.

Deal structure also determines which party retains regulatory licenses, contracts, and employee relationships. In regulated industries, such as healthcare, the acquiring company must obtain new licenses or demonstrate regulatory fitness independently. Failure to address these requirements before closing can halt operations or trigger enforcement action. The choice between asset and stock purchase is rarely neutral; it reshapes the buyer's risk profile and the seller's tax burden.

Due diligence is the investigation phase where the buyer examines the seller's financial records, contracts, litigation history, regulatory compliance, and operational practices. The buyer's counsel reviews representations and warranties in the purchase agreement, which are the seller's contractual promises about the accuracy of disclosed information. If a representation proves false after closing, the buyer may have a claim for breach and indemnification.

Disclosure schedules attached to the purchase agreement document exceptions to representations. A seller that fails to disclose a known liability or regulatory issue faces indemnification claims, even if the buyer conducted thorough due diligence. Courts generally hold sellers accountable for affirmative misstatement and material omissions, particularly in regulated sectors. In practice, disputes over what should have been disclosed rarely map neatly onto a single rule; they turn on the specificity of the representation, the buyer's access to information, and the materiality threshold in the agreement.

Many M&A transactions require regulatory approval or notification. Antitrust law prohibits mergers that substantially lessen competition. The Hart-Scott-Rodino Act requires parties to file with the Federal Trade Commission (FTC) and Department of Justice (DOJ) if the transaction exceeds specified size thresholds. Healthcare transactions, including hospital mergers and acquisitions and pharmacy mergers and acquisitions, face heightened scrutiny because regulators examine whether the combination reduces consumer choice or raises prices.

State attorneys general and local regulators may challenge deals on competitive grounds. Regulatory approval is not automatic; agencies may impose conditions, require divestitures, or block the transaction entirely. Parties often negotiate remedies—such as selling overlapping business units—to address competitive concerns and obtain clearance. Delay or denial of regulatory approval can extend deal timelines, increase costs, and sometimes kill the transaction altogether.

Indemnification clauses protect the buyer from losses arising from breach of the seller's representations or unknown liabilities. Sellers typically negotiate caps on indemnification exposure and time limits (survival periods) after which claims expire. Escrow arrangements hold back a portion of the purchase price to satisfy indemnification claims; if no claims arise during the survival period, the escrowed funds are released to the seller.

Indemnification disputes often hinge on causation and materiality. The buyer must prove that a loss resulted from breach of a representation and that the loss exceeds the agreement's threshold. Sellers frequently challenge whether the buyer mitigated losses or whether the loss was foreseeable. Courts examine the specific language of the representation, the disclosure schedule, and the purchase agreement's definition of indemnifiable losses. These disputes are often contested in court and can persist years after closing if the survival period permits.

Strategic considerations at closing include confirming that all known risks are documented in the disclosure schedules, negotiating reasonable survival periods and caps, and ensuring the escrow amount is sufficient to cover reasonably anticipated claims. Parties should also formalize post-closing cooperation obligations, dispute resolution procedures, and notice requirements to preserve evidence and reduce litigation risk.